Review
Oncology
Zahra Shokati Eshkiki, Shahram Agah, Seidamir Pasha Tabaeian, Meghdad Sedaghat, Fatemeh Dana, Atefeh Talebi, Abolfazl Akbari
Summary: The translation article points out that there is sufficient evidence to support the role of neoantigens in clinically successful immunotherapy. Several algorithms have been designed and optimized based on Next-Generation Sequencing and public databases to predict in silico the development of neoantigens and stimulate the development of T cell therapies, cancer vaccines, and other ongoing immunotherapy approaches.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2022)
Article
Immunology
Chiara M. Biatta, Michele Paudice, Marco Greppi, Veronica Parrella, Alessia Parodi, Giuseppa De Luca, Gianna Maria Cerruti, Serafina Mammoliti, Cinzia Caroti, Paola Menichini, Gilberto Fronza, Silvia Pesce, Emanuela Marcenaro, Valerio G. Vellone
Summary: This study investigated the concordance between immunohistochemical p53 staining and TP53 mutations in HGSOC, and explored prognostic differences between p53 overexpression and null expression groups. The results showed that all cases with a null immunohistochemical p53 expression had TP53 mutations, while 16 out of 18 cases with p53 overexpression had TP53 missense mutations. Follow-up data revealed a significant reduction in overall survival for the p53 null group. Therefore, immunohistochemical assay can serve as a reliable surrogate for TP53 mutations, and HGSOC with p53 null mutations are associated with a more aggressive subtype.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Cell Biology
Marine Bruand, David Barras, Marco Mina, Eleonora Ghisoni, Matteo Morotti, Evripidis Lanitis, Noemie Fahr, Mathieu Desbuisson, Alizee Grimm, Hualing Zhang, Chloe Chong, Julien Dagher, Sora Chee, Theodora Tsianou, Julien Dorier, Brian J. Stevenson, Christian Iseli, Catherine Ronet, Sara Bobisse, Raphael Genolet, Josephine Walton, Michal Bassani-Sternberg, Lana E. Kandalaft, Bing Ren, Iain McNeish, Elizabeth Swisher, Alexandre Harari, Mauro Delorenzi, Giovanni Ciriello, Melita Irving, Sylvie Rusakiewicz, Periklis G. Foukas, Fabio Martinon, Denarda Dangaj Laniti, George Coukos
Summary: This study investigates mechanisms of inflammation and immunoreactivity in ovarian tumors with homologous recombination deficiency (HRD). BRCA1 loss leads to transcriptional reprogramming and inflammation involving type I interferon (IFN) and STING. Genetic deletion or methylation of DNA-sensing/IFN genes or CCL5 chemokine can attenuate T cell inflammation. Tumor-intrinsic STING elimination reduces neoangiogenesis and reverses therapeutic resistance to immune checkpoint blockade. VEFG-A blockade synergizes with STING loss and immune checkpoint blockade to control tumor growth in HRD cancers.
Article
Ecology
Theo Busschau, Adriaan Jordaan, Werner Conradie, Savel R. Daniels
Summary: Comparative phylogeographic studies are lacking for southern African herpetofauna, despite their high diversity. This study statistically compared phylogeographic structure and divergence-time estimates among five co-distributed forest-living herpetofaunal taxa and identified congruent drivers of phylogeographic diversity.
JOURNAL OF BIOGEOGRAPHY
(2022)
Review
Immunology
Qiuting Zhang, Miao Xu
Summary: This article summarizes T-cell responses in EBV-related cancers, considering latency patterns, host immune status, and factors such as human leukocyte antigen (HLA) susceptibility that may affect immune outcomes. The authors also discuss the potential roles of EBV-specific T-cell responses in tumor microenvironments and describe T-cell immunotherapy strategies that harness EBV antigens.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Hubert Lam, Lisa K. McNeil, Hanna Starobinets, Victoria L. DeVault, Roger B. Cohen, Przemyslaw Twardowski, Melissa L. Johnson, Maura L. Gillison, Mark N. Stein, Ulka N. Vaishampayan, Arthur P. DeCillis, James J. Foti, Vijetha Vemulapalli, Emily Tjon, Kyle Ferber, Daniel B. DeOliveira, Wendy Broom, Parul Agnihotri, Elizabeth M. Jaffee, Kwok-Kin Wong, Charles G. Drake, Pamela M. Carroll, Thomas A. Davis, Jessica Baker Flechtner
Summary: The ATLAS bioassay is developed to identify neoantigens empirically by expressing patient-specific tumor mutations individually, revealing both stimulatory and inhibitory responses. Therapeutic immunization with stimulatory neoantigens protected animals, while immunization with inhibitory responses resulted in accelerated tumor growth. Empirical testing shows that T-cell responses to neoantigens are more nuanced than straightforward MHC antigen recognition and could impact cancer immunotherapy design.
Article
Oncology
Joseph A. Zundell, Takeshi Fukumoto, Jianhuang Lin, Nail Fatkhudinov, Timothy Nacarelli, Andrew Kossenkov, Qin Liu, Joel Cassel, Chih-Chi Andrew Hu, Shuai Wu, Rugang Zhang
Summary: The SWI/SNF chromatin-remodeling complex is frequently altered in human cancers, with the ARID1A mutation conferring sensitivity to inhibition of the IRE1 alpha-XBP1 pathway in ovarian clear cell carcinomas. Targeting the IRE1 alpha-XBP1 axis represents a promising therapeutic approach for ARID1A-mutant ovarian cancers, especially when combined with HDAC6 inhibition.
Article
Oncology
David A. Wheeler, Naoko Takebe, Toshinori Hinoue, Katherine A. Hoadley, Maria F. Cardenas, Alina M. Hamilton, Peter W. Laird, Linghua Wang, Adrienne Johnson, Ninad Dewal, Vincent Miller, David Pineyro, Manuel Castro de Moura, Manel Esteller, Hui Shen, Jean Claude Zenklusen, Roy Tarnuzzer, Lisa M. McShane, James Tricoli, Paul M. Williams, Irina Lubensky, Geraldine O'Sullivan-Coyne, Elise C. Kohn, Richard F. Little, Jeffrey White, Shakun Malik, Lyndsay Harris, Carol Weil, Alice P. Chen, Chris Karlovich, Brian Rodgers, Lalitha Shankar, Paula Jacobs, Tracy Nolan, Jianhong Hu, Donna M. Muzny, Harshavardhan Doddapaneni, Viktoriya Korchina, Julie Gastier-Foster, Jay Bowen, Kristen Leraas, Elijah F. Edmondson, James H. Doroshow, Barbara A. Conley, S. Percy Ivy, Louis M. Staudt
Summary: Genomic analysis has identified molecular mechanisms for exceptional responses to cancer therapy in a small fraction of patients with advanced disease, including DNA damage response, intracellular signaling, immune engagement, and genetic alterations. These analyses have revealed synthetic lethal relationships and rare genetic lesions that favor therapeutic success, providing valuable insights into oncogenic mechanisms influencing the response to cancer therapy.
Article
Multidisciplinary Sciences
Yunguang Sun, Ning Yang, Fransiscus E. Utama, Sameer S. Udhane, Junling Zhang, Amy R. Peck, Alicia Yanac, Katherine Duffey, John F. Langenheim, Vindhya Udhane, Guanjun Xia, Jess F. Peterson, Julie M. Jorns, Marja T. Nevalainen, Romain Rouet, Peter Schofield, Daniel Christ, Christopher J. Ormandy, Anne L. Rosenberg, Inna Chervoneva, Shirng-Wern Tsaih, Michael J. Flister, Serge Y. Fuchs, Kay-Uwe Wagner, Hallgeir Rui
Summary: A humanized prolactin mouse model was developed to establish therapy-naive ER+ breast cancer tumors and study treatment resistance mechanisms, revealing new insights into precision medicine approaches for this type of cancer.
Article
Biochemistry & Molecular Biology
Arsen Arakelyan, Ani Melkonyan, Siras Hakobyan, Uljana Boyarskih, Arman Simonyan, Lilit Nersisyan, Maria Nikoghosyan, Maxim Filipenko, Hans Binder
Summary: This study revealed significant differences in transcriptomic landscapes of breast and ovarian cancers associated with BRCA1 and BRCA2 mutations, indicating that these mutations affect different biological functions and have differential associations with phenotype characteristics and PARP-inhibitor gene signatures. Further investigations with larger groups of mutation carriers are needed to refine the understanding of the molecular mechanisms of breast and ovarian cancers.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Tanya T. Kwan, Amit M. Oza, Anna Tinker, Isabelle Ray-Coquard, Ana Oaknin, Carol Aghajanian, Domenica Lorusso, Nicoletta Colombo, Andrew Dean, Johanne Weberpals, Eric Severson, Lan-Thanh Vo, Sandra Goble, Lara Maloney, Thomas Harding, Scott H. Kaufmann, Jonathan A. Ledermann, Robert L. Coleman, Iain A. McNeish, Kevin K. Lin, Elizabeth M. Swisher
Summary: The study suggests that preexisting TP53 CHIP variants may be associated with the development of t-MNs after rucaparib treatment, indicating a potential genetic role in t-MNs development.
Article
Multidisciplinary Sciences
Seyed Pairawan, Argun Akcakanat, Scott Kopetz, Coya Tapia, Xiaofeng Zheng, Huiqin Chen, Min Jin Ha, Yasmeen Rizvi, Vijaykumar Holla, Jing Wang, Kurt W. Evans, Ming Zhao, Naifa Busaidy, Bingliang Fang, Jack A. Roth, Ecaterina Ileana Dumbrava, Funda Meric-Bernstam
Summary: Combination therapy with MEK inhibitor selumetinib and MDM2 inhibitor KRT-232 was evaluated in colon and thyroid cancer models. The study showed that the combination therapy had better antitumor efficacy than single drug therapy in both in vitro and in vivo settings.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Guillaume Beinse, Pierre-Alexandre Just, Marie-Aude Le Frere Belda, Pierre Laurent-Puig, Sebastien Jacques, Meriem Koual, Simon Garinet, Karen Leroy, Nicolas Delanoy, Helene Blons, Claire Gervais, Catherine Durdux, Charles Chapron, Francois Goldwasser, Benoit Terris, Cecile Badoual, Valerie Taly, Anne-Sophie Bats, Bruno Borghese, Jerome Alexandre
Summary: This study identified a common transcriptional profile shared by endometrial, breast, and ovarian cancers with homologous recombination deficiency (HRD). The RNAseq score derived from this profile was predictive of HRD and correlated with HRD in independent gynecological cancer datasets. The RNAseq HRD profile was associated with better overall survival in certain subtypes of these cancers and could potentially be used for prognostication and therapeutic decision-making.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Noam Levin, Biman C. Paria, Nolan R. Vale, Rami Yossef, Frank J. Lowery, Maria R. Parkhurst, Zhiya Yu, Maria Florentin, Gal Cafri, Jared J. Gartner, Mackenzie L. Shindorf, Lien T. Ngo, Satyajit Ray, Sanghyun P. Kim, Amy R. Copeland, Paul F. Robbins, Steven A. Rosenberg
Summary: This study identified T-cell receptors that recognize mutated RAS antigens with high specificity and avidity, potentially serving as promising reagents for adoptive cell therapies targeting RAS mutations in cancer patients.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Nina M. Clark, Emma A. Roberts, Catherine Fedorenko, Qin Sun, Marianne Dubard-Gault, Cynthia Handford, Rachel Yung, Heather H. Cheng, Jonathan G. Sham, Barbara M. Norquist, Meghan R. Flanagan
Summary: This retrospective cohort study evaluated the frequency of genetic testing in patients with breast, ovarian, pancreatic, and prostate cancers, and found an increase in testing over time. While guideline-concordant testing was high for breast cancer, there were gaps in concordance among patients with other cancers. Increasing provider and patient education, genetic counseling, and insurance coverage for testing among these patients may improve guideline adherence.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Maria R. Parkhurst, Paul F. Robbins, Eric Tran, Todd D. Prickett, Jared J. Gartner, Li Jia, Gabriel Ivey, Yong F. Li, Mona El-Gamil, Almin Lalani, Jessica S. Crystal, Abraham Sachs, Eric Groh, Satyajit Ray, Lien T. Ngo, Scott Kivitz, Anna Pasetto, Rami Yossef, Frank J. Lowery, Stephanie L. Goff, Winifred Lo, Gal Cafri, Drew C. Deniger, Parisa Malekzadeh, Mojgan Ahmadzadeh, John R. Wunderlich, Robert P. T. Somerville, Steven A. Rosenberg
Article
Immunology
Panagiota Maravelia, Lars Frelin, Yi Ni, Noelia Caro Perez, Gustaf Ahlen, Neetu Jagya, Georg Verch, Lieven Verhoye, Lena Pater, Magnus Johansson, Anna Pasetto, Philip Meuleman, Stephan Urban, Matti Sallberg
Summary: This study introduces a novel immunotherapy targeting viral entry for chronic HBV/HDV infections, which aims to activate PreS1-specific T cells and antibodies to block HBV entry, showing promising results in preventing and modulating HBV infection.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Review
Immunology
Matti Sallberg, Anna Pasetto
FRONTIERS IN IMMUNOLOGY
(2020)
Review
Cell Biology
Katie Healy, Anna Pasetto, Michal J. Sobkowiak, Chai Fen Soon, Markus Cornberg, Soo Aleman, Margaret Sallberg Chen
Article
Oncology
Biman C. Paria, Noam Levin, Frank J. Lowery, Anna Pasetto, Drew C. Deniger, Maria R. Parkhurst, Rami Yossef, Sanghyun P. Kim, Maria Florentin, Lien T. Ngo, Satyajit Ray, Sri Krishna, Paul F. Robbins, Steven A. Rosenberg
Summary: This study introduces a novel platform for rapid and efficient identification and evaluation of neoantigen-specific TCRs without the need for recombinant cloning techniques. Validation and comparison with conventional methods show that this approach can significantly shorten TCR discovery time and increase testing throughput.
JOURNAL OF IMMUNOTHERAPY
(2021)
Editorial Material
Oncology
Anna Pasetto
Meeting Abstract
Oncology
P. Maravelia, A. P. Potti, T. Sekine, D. S. N. Silva, K. Healy, M. Chrobok, C. Jorns, M. Sallberg, M. Buggert, A. Pasetto
ANNALS OF ONCOLOGY
(2020)
Review
Immunology
Anna Pasetto, Yong-Chen Lu
Summary: T cells are essential in immune responses and cancer immunotherapy. Single-cell sequencing techniques have enabled scientists to study T cells at a deeper level, including T-cell receptor and transcriptome analysis. These techniques also aid in the identification of T-cell neoantigens, advancing T-cell mediated cancer therapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Panagiota Maravelia, Daniela Nascimento Silva, Giulia Rovesti, Michael Chrobok, Per Stal, Yong-Chen Lu, Anna Pasetto
Summary: Hepatocellular carcinoma (HCC) is a deadly cancer with limited treatment options, but immunotherapies have shown promising outcomes for advanced cases. However, there is a need for more accurate predictive markers. Circulating biomarkers such as circulating tumor cells and circulating tumor DNA could provide a non-invasive means to monitor treatment responses and disease progression in HCC.
Review
Biochemistry & Molecular Biology
Lucia Mazzotti, Anna Gaimari, Sara Bravaccini, Roberta Maltoni, Claudio Cerchione, Manel Juan, Europa Azucena-Gonzalez Navarro, Anna Pasetto, Daniela Nascimento Silva, Valentina Ancarani, Vittorio Sambri, Luana Calabro, Giovanni Martinelli, Massimiliano Mazza
Summary: The immune system is influenced by individual characteristics and exposures. Pathological conditions depend on the response of the immune system and TCR repertoire sequencing can provide insights into its behavior. Understanding the technology and applications of TCR repertoire sequencing is crucial for researchers.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cell Biology
Rigel J. Kishton, Shashank J. Patel, Amy E. Decker, Suman K. Vodnala, Maggie Cam, Tori N. Yamamoto, Yogin Patel, Madhusudhanan Sukumar, Zhiya Yu, Michelle Ji, Amanda N. Henning, Devikala Gurusamy, Douglas C. Palmer, Roxana A. Stefanescu, Andrew T. Girvin, Winifred Lo, Anna Pasetto, Parisa Malekzadeh, Drew C. Deniger, Kris C. Wood, Neville E. Sanjana, Nicholas P. Restifo
Summary: A three-step approach was used to identify cancer genes that inhibit T cell immunity, and BIRC2 was identified as a potential target for combination therapy with adoptive T cell therapies to increase efficacy.
Article
Immunology
Daniela Nascimento Silva, Michael Chrobok, Giulia Rovesti, Katie Healy, Arnika Kathleen Wagner, Panagiota Maravelia, Francesca Gatto, Massimiliano Mazza, Lucia Mazzotti, Volker Lohmann, Margaret Sallberg Chen, Matti Sallberg, Marcus Buggert, Anna Pasetto
Summary: Researchers provide a pipeline for the process development and clinical-scale manufacturing of TCR-T cells in academia, addressing the need for cancer and chronic viral infection treatments. They successfully reproduced the functional characteristics of specific TCRs and demonstrated the similarity and efficient production of TCR-T cell products.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Gastroenterology & Hepatology
Rani Burm, Panagiota Maravelia, Gustaf Ahlen, Sandra Ciesek, Noelia Caro Perez, Anna Pasetto, Stephan Urban, Freya Van Houtte, Lieven Verhoye, Heiner Wedemeyer, Magnus Johansson, Lars Frelin, Matti Sallberg, Philip Meuleman
Summary: This study demonstrates the immunogenicity and effectiveness of preS1-HDAg immunotherapy in preventing HBV and HDV infections both in vitro and in vivo. The vaccine can complement current and future therapies for the control of chronic HBV and HDV infection.
Meeting Abstract
Cell & Tissue Engineering
D. N. Silva, M. Chrobok, K. Healy, P. Maravelia, G. Ahlen, A. Pasetto, M. Sallberg
Meeting Abstract
Biotechnology & Applied Microbiology
Magnus Johansson, Lars Frelin, Panagiota Maravelia, Naveed Asghar, Wessam Melik, Noelia Caro-Perez, Anna Pasetto, Gustaf Ahlen, Matti Sallberg